© Globe Newswire
25.02.2025
IBAB
LISTED
EURONEXT
IBA and Jabil sign contract to install a Be-Wide X-ray solution in Mississippi, USA
News Preview
...
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
ERF
LISTED
EURONEXT
Eurofins Softlines & Hardlines Supports Toy Industry Amid Proposed European Toy Safety Regulation with Dedicated Services
News Preview
Eurofins Softlines & Hardlines, a full-service testing and certification provider for retailers, brands, importers and manufacturers of consumer products, today announces services to support toy companies with their preparation and transition to the proposed European Toy Safety Regulation (EU TSR). The draft EU TSR introduces stricter safety m...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.02.2025
CELC
LISTED
NASDAQ
Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences
News Preview
MINNEAPOLIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following inves...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
25.02.2025
LIVN
LISTED
NASDAQ
LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance.
Financial Summary and Highlights(1)
Fourth-quarter revenue of $321.8 million increased 3.8% on a reported basis, 4.7% on a constant-currency basis, and 6.8% on an organic basis...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
25.02.2025
ORNBV
LISTED
HEL
Orion Corporation: The Board of Directors of Orion Corporation decided on incentive programs for the company’s key persons
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 25 FEBRUARY 2025 at 12.35 EET Orion Corporation: The Board of Directors of Orion Corporation decided on incentive programs for the company’s key persons...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.02.2025
ORNBV
LISTED
HEL
Notice to the Annual General Meeting of Orion Corporation
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE / NOTICE TO GENERAL MEETING 25 FEBRUARY 2025 at 12:15 EET...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.02.2025
ORNBV
LISTED
HEL
Orion Group Financial Statement Release January–December 2024
News Preview
ORION CORPORATION FINANCIAL STATEMENT RELEASE 1–12/2024 25 FEBRUARY 2025 at 12:00 EET...
Themefolio
Profiler
Peergroup
© EQS Newswire
25.02.2025
EUZ
LISTED
XETR
Eckert & Ziegler stellt Geschäftskontinuität nach Cyberangriff sicher
News Preview
Berlin, 25. Februar 2025. Nach dem Angriff auf die IT-Infrastruktur der Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) Anfang Februar können die Geschäfte der Unternehmensgruppe in den meisten Bereichen weiterlaufen. Vereinzelt gibt es aufgrund der schrittweisen Wiederherstellung an der ein oder anderen Stelle noch Einschränkungen. Seit dieser......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.02.2025
EUZ
LISTED
XETR
Eckert & Ziegler Ensures Business Continuity After Cyber-Attack
News Preview
Berlin, 25 February 2025. Following a cyber-attack on the IT infrastructure of Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) at the beginning of February, the Group's business operations can continue in most areas. In a few cases, there are still restrictions due to the gradual restoration at one point or another.
As of this week, all essent......
Themefolio
Profiler
Peergroup
© ACCESS Newswire
25.02.2025
AGFB
LISTED
EURONEXT
Incredible KLAS Outcomes! AGFA HealthCare Achieves Triple KLAS Wins and Excels in PACS Radiology & Cardiology Ratings in USA!
News Preview
GREENVILLE, SOUTH CAROLINA / ACCESS Newswire / February 25, 2025 / AGFA HealthCare proudly celebrates multiple KLAS distinctions, securing two #1 Best in KLAS awards for XERO® Viewer and VNA, alongside the KLAS Most Improved Software Product award. Additionally, AGFA HealthCare earned exceptional ratings in PACS Radiology and Cardiology review...
Themefolio
Profiler
Peergroup
© PR Newswire
25.02.2025
IMMNOV
LISTED
STO
Immunovia Publishes Full Year Report for 2024
News Preview
LUND, Sweden, Feb. 25, 2025 /PRNewswire/ --
October-December 2024
Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155).Net earnings were 3,1 MSEK (-49,0) as a result of unrealized exchange rate effects due to a higher dollar rate on the transactions to finance operations in Immunovia Inc.Operating losses were -30...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.02.2025
KDEV
LISTED
STO
Karolinska Development’s portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01
News Preview
STOCKHOLM, SWEDEN February 25, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has dosed the first patient in the phase 2a part of the GOAL-HF1 clinical study. The study will evaluate AnaCardio’s drug candidate AC01 in patients with heart failure and reduced ejection fraction. Study resu...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
25.02.2025
FYB
LISTED
XETR
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
News Preview
Press Release // February 25, 2025
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
FYB203 (aflibercept) approved in the UK for the treatment of neovascular age-related macular degeneration (nAMD) and several other severe retinal diseases
UK market authorization......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.02.2025
FYB
LISTED
XETR
Formycon erhält Zulassung in Großbritannien für FYB203 (Aflibercept), ein Biosimilar zu Eylea®, unter dem Markennamen AHZANTIVE®
News Preview
Pressemitteilung // 25. Februar 2025
Formycon erhält Zulassung in Großbritannien für FYB203 (Aflibercept), ein Biosimilar zu Eylea®, unter dem Markennamen AHZANTIVE®
FYB203 (Aflibercept) in Großbritannien zur Behandlung der neovaskulären altersbedingten Makuladegeneration (nAMD) sowie weiterer schwerer Netzhauterkrankungen zugelassen
Britische ......
Themefolio
Profiler
Peergroup
© Globe Newswire
25.02.2025
BAVA
LISTED
CPH
Bavarian Nordic Partners with Biological E Limited to Expand Global Access to Chikungunya Vaccine
News Preview
COPENHAGEN, Denmark, February 25, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced a strategic partnership with Biological E. Limited (BE) to expand access to Bavarian Nordic’s chikungunya vaccine in low- and middle-income (LMIC) countries....
Themefolio
Profiler
Peergroup
© BusinessWire
25.02.2025
BLUE
LISTED
NASDAQ
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE
News Preview
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of bluebird bio, Inc. (NasdaqGS: BLUE) to Carlyle Group and SK Capital Partners, LP. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
TEM
LISTED
NASDAQ
Tempus Reports Fourth Quarter and Full Year 2024 Results
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter and year ended December 31, 2024.
Year-over-year revenue growth accelerated to 35.8% in the fourth quarter of 2024
Gross profit growth accelerated to 49.7% in the four...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
ICLR
LISTED
NASDAQ
ICLR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that ICON PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against ICON PLC (“ICON” or “the Company”) (NASDAQ: ICLR) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged violations of...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.02.2025
ATAI
LISTED
NASDAQ
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
News Preview
NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the TD Cowen 45th Annual Health Care Conference i...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.02.2025
RXRX
LISTED
NASDAQ
Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
News Preview
Company to host public (L)earnings call on February 28th at 8:30 am ET / 6:30 am MT / 1:30 pm GMT Company to host public (L)earnings call on February 28th at 8:30 am ET / 6:30 am MT / 1:30 pm GMT...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.02.2025
SKYE
LISTED
NASDAQ
Skye Bioscience to Participate in SXSW Session on Obesity
News Preview
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, is pleased to announce the participation of Punit Dhillon, Chief Executive Officer, in a South by Southwest panel ses...
Themefolio
Profiler
Peergroup
© EQS Newswire
24.02.2025
FYB
LISTED
XETR
First Berlin Equity Research GmbH: Formycon AG | Rating: Buy
News Preview
Original-Research: Formycon AG - from First Berlin Equity Research GmbH
24.02.2025 / 11:25 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certai......
Themefolio
Profiler
Peergroup
© PR Newswire
24.02.2025
SECT_B
LISTED
STO
Enhancing radiology workflows: Sectra and Siemens Healthineers enable seamless integration across systems for better patient care
News Preview
LINKÖPING, Sweden, Feb. 24, 2025 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) and Siemens Healthineers AG are collaborating to improve radiologists' diagnostic capabilities and, as such, patient care through a seamless integration. The two companies are working together to enable radiologists to...
Themefolio
Profiler
Peergroup
© PR Newswire
24.02.2025
INDV
LISTED
NASDAQ
Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection
News Preview
Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD)
RICHMOND, Va., Feb. 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV), a global leader in addiction treatment, today announced that the U.S. Food and Drug...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
ALM
LISTED
BME
Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline
News Preview
Almirall, S.A. (ALM):
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250223477772/en/Almirall HQ in Barcelona (Photo: Business Wire)
Financial highlights (€ rounded million)
2024
2023
Variation
Total Revenue
990.6
898.8
10.2%
Ne...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.02.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO
News Preview
OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO...
Themefolio
Profiler
Peergroup
© PR Newswire
21.02.2025
IMMNOV
LISTED
STO
Immunovia initiates search for a new CFO to support commercialization in the USA
News Preview
LUND, Sweden, Feb. 21, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that it will be hiring a new Chief Financial Officer (CFO) as its focus turns to the US market.
As Immunovia transitions to commercializing its test in the second half of 2025, the company's financial lead...
Themefolio
Profiler
Peergroup
© PR Newswire
21.02.2025
RAY B
LISTED
STO
Record date for dividend - correction
News Preview
STOCKHOLM, Feb. 21, 2025 /PRNewswire/ -- The Board of RaySearch Laboratories AB (publ) proposes a dividend for the full-year 2024 of 3.00 SEK per share (0.70). Record day for the dividend is proposed to May 26, 2025, and the dividend is expected to be paid on May 30, 2025. The Year-end report 2024 stated the wrong dividend record date.
CONTACT:...
Themefolio
Profiler
Peergroup
© BusinessWire
21.02.2025
BLUE
LISTED
NASDAQ
Shareholder Alert: Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for its Public Shareholders
News Preview
Ademi LLP is investigating bluebird (Nasdaq: BLUE) for possible breaches of fiduciary duty and other violations of law in its transaction with Carlyle and SK Capital.
Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation t...
Themefolio
Profiler
Peergroup
© BusinessWire
21.02.2025
LIVN
LISTED
NASDAQ
LivaNova to Present at the Barclays Global Healthcare Conference
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The presentation will take place at 2:00 p.m. Eastern Time on Tuesday, March 11.
The discussion will be available to...
Themefolio
Profiler
Peergroup
© BusinessWire
21.02.2025
BLUE
LISTED
NASDAQ
BLUE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of bluebird bio, Inc. Is Fair to Shareholders
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of bluebird bio, Inc. (NASDAQ: BLUE) to Carlyle Group and SK Capital Partners, LP is fair to bluebird shareholders. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holde...
Themefolio
Profiler
Peergroup
© BusinessWire
21.02.2025
BLUE
LISTED
NASDAQ
bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle (NASDAQ: CG) and SK Capital Partners, LP (“SK Capital”) in collaboration with a team of highly experienced biotech executives. David Meek, former CEO of Mirati Therapeutic...
Themefolio
Profiler
Peergroup
© PR Newswire
21.02.2025
VITR
LISTED
STO
The Vitrolife Group appoints Ermanno Sironi as Chief Operating Officer
News Preview
GOTHENBURG, Sweden, Feb. 21, 2025 /PRNewswire/ -- The Vitrolife Group is strengthening the executive management team with the introduction of the role of Chief Operating Officer (COO), appointing Ermanno Sironi to the position effective immediately.
The COO will oversee the three business areas, Consumables, Technologies and Genetics as well as...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.02.2025
MDGL
LISTED
NASDAQ
Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference
News Preview
CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET....
Themefolio
Profiler
Peergroup
© Globe Newswire
21.02.2025
NSIS B
LISTED
CPH
Change to the Executive Leadership Team
News Preview
Jacob Vishof Paulsen will be leaving his position as Executive Vice President of Food & Beverage Biosolutions, as he has accepted a role outside of Novonesis, effective March 31, 2025....
Themefolio
Profiler
Peergroup
© PR Newswire
21.02.2025
IMMNOV
LISTED
STO
Invitation to Immunovia's Q4 presentation
News Preview
LUND, Sweden, Feb. 21, 2025 /PRNewswire/ -- Immunovia will publish its full year 2024 results on February 25, 2025 at 8:30 am CET. Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET. The report together with the presentation slides will be available at www.immunovia.com.
Jeff Borcherding, CEO and P...
Themefolio
Profiler
Peergroup
© PR Newswire
21.02.2025
RAY B
LISTED
STO
RaySearch Laboratories: Year-end report 2024
News Preview
STOCKHOLM, Feb. 21, 2025 /PRNewswire/ --
FOURTH QUARTER (OCTOBER - DECEMBER 2024)
Order intake SEK 305.0 M (317.7)Net sales SEK 322.7 (299.6) Operating profit SEK 73.6 M (44.4)Profit after tax SEK 60.0 M (31.5)Earnings per share before/after dilution SEK 1.75 (0.92)Cash flow from operating activities SEK 102.9 M (115.8) Order backlog SEK 1,813.2...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.02.2025
GNFT
LISTED
EURONEXT
GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders’ general meeting
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 21, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces that it has signed Put Option Agreements with 2025 OCEANEs holders and the con...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.02.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO
News Preview
OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic ColitisIn Oral Presentation at 20th Congress of ECCO...
Themefolio
Profiler
Peergroup
© BusinessWire
20.02.2025
DFTX
LISTED
NASDAQ
MindMed to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025
News Preview
Mind Medicine (MindMed) Inc. (Nasdaq: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a live webcast at 8:00 a.m. ET on Thursday, March 6, 2025 to report financial results for the fourth quarter and year ended...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.02.2025
GMAB
LISTED
CPH
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma
News Preview
Media ReleaseCOPENHAGEN, Denmark; February 20, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.02.2025
ZEAL
LISTED
CPH
Correction: Zealand Pharma Announces Financial Results for the Full Year 2024
News Preview
Company announcement – No. 2 / 2025...
Themefolio
Profiler
Peergroup
© PR Newswire
20.02.2025
SOBI
LISTED
STO
EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN
News Preview
STOCKHOLM, Feb. 20, 2025 /PRNewswire/ -- Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare, c...
Themefolio
Profiler
Peergroup
© PR Newswire
20.02.2025
INDV
LISTED
NASDAQ
Indivior Announces FY and Q4 2024 Financial Results
News Preview
SLOUGH, United Kingdom and RICHMOND, Va., Feb. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024. The earnings release, investor presentation and webcast are available at www.indivior.com....
Themefolio
Profiler
Peergroup
© PR Newswire
20.02.2025
BIOA B
LISTED
STO
BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
News Preview
STOCKHOLM, Feb. 20, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from the U.S. Federal Trade Commission (FTC) for BioArctic to out-license its PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program to Bristol Myers Squi...
Themefolio
Profiler
Peergroup
© PR Newswire
20.02.2025
BIOA B
LISTED
STO
BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
News Preview
STOCKHOLM, Feb. 20, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that BioArctic and its partner Bristol Myers Squibb (NYSE: BMY) have received clearance from the U.S. Federal Trade Commission (FTC) for BioArctic to out-license its PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody program to Bristol Myers Squi...
Themefolio
Profiler
Peergroup
© EQS Newswire
20.02.2025
FYB
LISTED
XETR
Formycon präsentiert klinische Daten zu Ustekinumab-Biosimilar FYB202 auf dem ECCO-Kongress in Berlin
News Preview
Pressemitteilung // 20. Februar 2025
Formycon präsentiert klinische Daten zu Ustekinumab-Biosimilar FYB202 auf dem ECCO-Kongress in Berlin
Planegg-Martinsried - Die Formycon AG (FWB: FYB, Prime Standard) wird auf dem diesjährigen Kongress der European Crohn’s and Colitis Organisation (ECCO), der vom 19.02.2025 bis 22.02.2025 in Berlin stattfi......
Themefolio
Profiler
Peergroup
© EQS Newswire
20.02.2025
FYB
LISTED
XETR
Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
News Preview
Press Release // February 20, 2025
Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, Prime Standard, “Formycon”) will present an overview of the comparative data of the ustekinumab biosimilar FYB202 at this year's Congress of the European Croh......
Themefolio
Profiler
Peergroup
© Globe Newswire
20.02.2025
FAGR
LISTED
EURONEXT
Fagron delivers exceptional performance with 14% topline growth and 17% increase in REBITDA for FY 2024
News Preview
Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 20 February 2025 – 7AM CET...
Themefolio
Profiler
Peergroup
© Globe Newswire
20.02.2025
ZEAL
LISTED
CPH
Zealand Pharma Announces Financial Results for the Full Year 2024
News Preview
Company announcement – No. 2 / 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.02.2025
POAI
LISTED
NASDAQ
Predictive Oncology Closes Registered Direct Offering
News Preview
PITTSBURGH, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or the “Company”), a leader in AI-driven drug discovery and biologics, today closed its previously announced registered direct offering for the purchase and sale of 363,336 shares of common stock at a purchase price of $1.50 per share pric...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
ICLR
LISTED
NASDAQ
ICON Reports Fourth Quarter and Full Year 2024 Results
News Preview
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the fourth quarter and full year ended December 31, 2024.
CEO, Dr. Steve Cutler commented, “ICON’s results in quarter four were in-line with our expectations as we continue to manage through a challenging t...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
TEM
LISTED
NASDAQ
Tempus to Present at TD Cowen's 45th Annual Health Care Conference
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the TD Cowen 45th Annual Health Care Conference on March 3-5, 2025 in Boston, MA.
Tempus’ Chief Financial Officer, Jim Rogers, will participate in a fireside discussion at the conference on Monday, March 3...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.02.2025
GMAB
LISTED
CPH
Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference
News Preview
Media ReleaseCOPENHAGEN, Denmark; February 19, 2025Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano and Chief Development Officer Judith Klimovsky will participate in a fireside chat at the 45th Annual TD Cowen Health Care Conference in Boston, Massachusetts at 1:50 PM EST (7:50 PM CET) on March 3, 2025. A w...
Themefolio
Profiler
Peergroup
© BusinessWire
19.02.2025
AMRX
LISTED
NASDAQ
Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
News Preview
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment of moderately active ulcerative colitis in adults. Additionally, the Company has received approval from the U.S. Food an...
Themefolio
Profiler
Peergroup
© Globe Newswire
19.02.2025
IMCR
LISTED
NASDAQ
Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025
News Preview
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 19 February 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious disease...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.02.2025
RXRX
LISTED
NASDAQ
Altitude Lab Startups Raise $154M in Capital
News Preview
The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones The Accelerator Awards $150,000 Fellowship to Elnora AI CEO, and Announces Key Cohort Milestones...
Themefolio
Profiler
Peergroup
© Globe Newswire
18.02.2025
IBAB
LISTED
EURONEXT
Notice of Capital Markets Day - Save the Date
News Preview
Louvain-la-Neuve, Belgium, 18 February, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, will host a Capital Markets Day (CMD) for investors and analysts on Monday 7 April 2025 at 2pm CET / 1pm GMT / 8am ET....
Themefolio
Profiler
Peergroup
© PR Newswire
18.02.2025
CYRX
LISTED
NASDAQ
Cryoport to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
News Preview
NASHVILLE, Tenn., Feb. 18, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in supply chain solutions for the life sciences industry, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2024 on Tuesday, March 4, 2025 after U.S. markets c...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
TEM
LISTED
NASDAQ
Tempus to Participate in the Morgan Stanley Technology, Media and Telecom Conference
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley Technology, Media & Telecom Conference on Monday, March 3-6, 2025, held in San Francisco, CA.
Tempus Founder and CEO, Eric Lefkofsky, will participate in a fireside discussion at...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
